Table 2 primary endpoint analysis at W48 of the 382 patients switching to E/C/F/TDF
Present study n = 382 | S trategy–PI Arribas et al. [9] n = 290 | Strategy– NNRTI Pozniak et al. [10] n = 290 | |
|---|---|---|---|
Success (patients with VL < 50 copies/mL at W48) | 314 (82.0) [95% CI 78.4–86.0] | 272 (94.0) | 271 (93.0) |
Virologic failure (VL ≥ 50 copies/mL at W48) | 13(3.5%) [95% CI 3.64–8.41] | 2 (1.0) | 3 (1.0) |
Genotype available at failure | 6/13 | 0 (0.0) | 1 |
Resistance to INSTIs | 5/6 | 0 (0.0) | 0 |
No data | 55 (14.5) 95% CI 10.9–17.9] | 16 (6.0) | 16 (6.0) |
Adverse events leading to treatment discontinuation | 23 (6.0) [95% CI 3.6–8.4] | 6 (2.0) | 6 (2.0) |
Other reasons for treatment discontinuation and lost to follow–up | 31 (8.2)* [95% CI 5.6–11.4] | 11 (3.8) | 11 (3.8) |
Death | 1 (0.3) [95% CI 0.0–1.7] | 0 (0.0) | 1 (0.3) |
Total | 382 (100.0) | 290 (100.0) | 290 (100.0) |